MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$36,975K
EPS
-$0.4
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenue-License
--26,706* --
Restructuring
-0* 0 0
Total revenue
127,199 -164,859 114,449
In-process research and development
-0* 0 0
Product
-3,583* --
License
--1,028* --
Total revenue-Product
-156,394* --
Cost of goods sold
1,950 2,554 1,585 1,521
Research and development
57,094 57,870 51,890 49,362
Selling, general and administrative
80,254 101,695 86,453 76,216
Royalty expense
24,816 ---
Total operating expenses
164,114 162,119 139,928 127,099
Operating loss
-36,915 -32,431 24,931 -12,650
Interest income
2,584 2,592 3,047 3,287
Interest expense
2,300 2,294 2,751 2,846
Other (expense) income, net
-91 11,068 487 -526
Total other income, net
193 11,366 783 -85
Loss from continuing operations before income tax
-36,722 -21,065 25,714 -12,735
Income tax benefit (provision) on continuing operations
-120 921 8 20
Loss from continuing operations, net of tax
-36,602 -21,986 25,706 -12,755
Loss from discontinued operations, net of tax
-500 24,715 0 0
Unrealized gain (loss) on defined benefit pension plan
--219 --
Net gain
-37,102 2,729 25,706 -12,755
Foreign currency translation gain (loss)
447 -243 -284 268
Unrealized loss on marketable debt securities
-320 -111 42 -237
Comprehensive gain
-36,975 2,594 25,464 -12,724
Basic EPS
-0.4 0.029 0.29 -0.14
Diluted EPS
-0.4 0.034 0.28 -0.14
Basic Average Shares
91,868,862 90,315,235 89,230,420 88,945,624
Diluted Average Shares
91,868,862 76,927,095 102,618,560 88,945,624
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive gain-$36,975K (11.94%↑ Y/Y)Foreign currencytranslation gain (loss)$447K (165.16%↑ Y/Y)Net gain-$37,102K (10.00%↑ Y/Y)Unrealized loss onmarketable debt securities-$320K (-315.58%↓ Y/Y)Loss from continuingoperations, net of tax-$36,602K (11.22%↑ Y/Y)Loss fromdiscontinued operations, net...-$500K Income tax benefit(provision) on continuing...-$120K (-407.69%↓ Y/Y)Interest income$2,584K (-31.91%↓ Y/Y)FILSPARI$105,152K Tiopronin Products$19,340K Loss from continuingoperations before income...-$36,722K (10.84%↑ Y/Y)Total other income,net$193K (-87.02%↓ Y/Y)Product$124,492K (9835.51%↑ Y/Y)License$2,707K (-20.99%↓ Y/Y)Interest expense$2,300K (-19.50%↓ Y/Y)Other (expense)income, net-$91K (-116.58%↓ Y/Y)Operating loss-$36,915K (13.50%↑ Y/Y)Total revenue$127,199K (55.63%↑ Y/Y)Total operatingexpenses$164,114K (31.92%↑ Y/Y)Selling, general andadministrative$80,254K (10.18%↑ Y/Y)Research and development$57,094K (21.76%↑ Y/Y)Royalty expense$24,816K Cost of goods sold$1,950K (-58.32%↓ Y/Y)

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics, Inc. (TVTX)